The Regulatory Services Core (RSC) provides oversight and coordination for all functions within the GNL required to support and conduct studies in accordance with the FDA's G LP regulations, as outlined in the Code of Federal Regulations, Title 21, Part 58 (21 CFR Part 58), and associated guidance documents. It is anticipated that these studies will involve development and validation of animal models for biodefense and emerging infectious disease agents, as well as pre-clinical testing of candidate vaccines and therapeutics, including testing under the FDA Animal Rule (21 CFR Parts 314 and 601) and/or generation of safety and efficacy data that might support licensure under an Emergency Use Authorization. The RSC will be responsible for coordination of efforts amongst individual investigators, other core laboratories (both within and outside the GNL), GNL management, UTMB's Institutional GLP program office, the NIH, the FDA and industry, to ensure the quality and integrity of data generated in these studies.

Public Health Relevance

The activities of the RCC are essential to the mission of the GNL. The development of vaccines, therapeutics and diagnostic assays for use against biodefense-related infectious disease agents will require that these products be tested and evaluated under high biocontainment conditions in a manner compliant with the GLP regulations, particularly in instances where product approval by the FDA will occur via the

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
National Biocontainment Laboratory Operation Cooperative Agreement (UC7)
Project #
5UC7AI094660-04
Application #
8820995
Study Section
Special Emphasis Panel (ZAI1-PRJ-M (J1))
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
4
Fiscal Year
2014
Total Cost
$622,710
Indirect Cost
Name
University of Texas Medical Br Galveston
Department
Type
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Thi, Emily P; Lee, Amy C H; Geisbert, Joan B et al. (2016) Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA. Nat Microbiol 1:16142
Satterfield, Benjamin A; Cross, Robert W; Fenton, Karla A et al. (2016) Nipah Virus C and W Proteins Contribute to Respiratory Disease in Ferrets. J Virol 90:6326-43
Agrawal, Anurodh Shankar; Ying, Tianlei; Tao, Xinrong et al. (2016) Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. Sci Rep 6:31629
Santos, Rodrigo I; Hermance, Meghan E; Gelman, Benjamin B et al. (2016) Spinal Cord Ventral Horns and Lymphoid Organ Involvement in Powassan Virus Infection in a Mouse Model. Viruses 8:
Cross, Robert W; Mire, Chad E; Branco, Luis M et al. (2016) Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antiviral Res 133:218-22
Mire, Chad E; Geisbert, Joan B; Agans, Krystle N et al. (2016) Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates. J Infect Dis 214:S367-S374
Mire, Chad E; Geisbert, Joan B; Agans, Krystle N et al. (2016) Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus. J Infect Dis 214:S263-S267
Cross, Robert W; Mire, Chad E; Borisevich, Viktoriya et al. (2016) The Domestic Ferret (Mustela putorius furo) as a Lethal Infection Model for 3 Species of Ebolavirus. J Infect Dis 214:565-9
Mire, Chad E; Geisbert, Thomas W; Feldmann, Heinz et al. (2016) Ebola virus vaccines - reality or fiction? Expert Rev Vaccines 15:1421-1430
Olsen, Michelle E; Filone, Claire Marie; Rozelle, Dan et al. (2016) Polyamines and Hypusination Are Required for Ebolavirus Gene Expression and Replication. MBio 7:

Showing the most recent 10 out of 52 publications